Controlled drug delivery is a matter of interest to numerous scientists from various domains,
as well as an essential issue for society as a whole. In the treatment of many diseases, it is …

Cardiovascular stent restenosis remains a major challenge in interventional treatment of
cardiovascular occlusive disease. Although the changes in arterial mechanical environment …

The pharmaceutical industry is facing enormous challenges, including reduced efficiency,
stagnant success rate, patent expirations for key drugs, fierce price competition from …

In drug eluting stent technologies, an increased demand for better control, higher reliability,
and enhanced performances of drug delivery systems emerged in the last years and thus …

Aims In-stent restenosis and late stent thrombosis are complications associated with the use
of metallic and drug-coated stents. Strategies that inhibit vascular smooth muscle cell (SMC) …

Low‐pressure plasma‐polymerized ethylene film coatings rich in bonded oxygen groups (L‐
PPE: O) were deposited on poly (ethylene terephthalate; PET) in order to act as hosts for …

Backgrounds Drug-eluting stents (DES) with biodegradable polymers have been developed
to address the risk of thrombosis associated with first-generation DES. We aimed to …

Background Percutaneous coronary intervention is widely used for the treatment of coronary
artery disease; however, significant challenges such as restenosis remain. Key to solving …

Coronary artery disease (CAD) is still the leading cause of death throughout the world. Metal
stents are used to widen narrowed arteries. In addition, drug-eluting stents (DES) are widely …

The value of restenosis after percutaneous coronary intervention (PCI) is recognized
worldwide, especially for diabetic patients. Interleukin-1/Toll-like receptor (IL-1/TLR) …